支持药品审批的临床研究报告可及性:一项横断面评估
该横断面研究评估了2021年收入最高的30种药品的FDA授权药品标签中报告的行业资助临床试验的临床研究报告(CSR)可及性。316项试验中,70项(22%)的CSR可从公共数据库下载,183项(58%)的CSR符合独立研究者向申办方申请的条件,合计218项(69%)的CSR可公开下载和/或可申请获取。
要点
- 316项支持30种药品审批的行业资助临床试验中,仅70项(22%)的CSR可从公共数据库直接下载。
- 183项(58%)的CSR符合独立研究者通过研究提案向申办方申请获取的条件。
- 合计218项(69%)的CSR可公开下载和/或可向申办方申请获取。
核心结论
- 支持30种抽样药品监管审批的临床试验中,69%的CSR可获取,但仅22%可直接从监管机构下载,其余需向研究申办方正式申请。
研究设计与样本
- 横断面研究,评估2021年收入最高的30种药品的FDA授权药品标签中报告的行业资助临床试验的CSR可及性。
- 共纳入316项行业资助临床试验,判断CSR是否可从公共数据库下载及是否符合独立研究者向申办方申请的条件。
主要发现
- 316项试验中,70项(22%)的CSR可公开下载,其中37项来自EMA数据库,40项来自Health Canada数据库。
- 制药公司平台不提供CSR直接下载,但申办方确认316项试验中183项(58%)的CSR符合独立研究者提交研究提案申请获取的条件。
- 合计218项(69%)的抽样临床试验的CSR可公开下载和/或可向试验申办方申请获取。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Clinical study reports (CSRs) are highly detailed documents that play a pivotal role in medicine approval processes. Though not historically publicly available, in recent years, major entities including the European Medicines Agency (EMA), Health Canada, and the US Food and Drug Administration (FDA) have highlighted the importance of CSR accessibility. The primary objective herein was to determine the proportion of CSRs that support medicine approvals available for public download as well as the proportion eligible for independent researcher request via the study sponsor. STUDY DESIGN AND SETTING: This cross-sectional study examined the accessibility of CSRs from industry-sponsored clinical trials whose results were reported in the FDA-authorized drug labels of the top 30 highest-revenue medicines of 2021. We determined (1) whether the CSRs were available for download from a public repository, and (2) whether the CSRs were eligible for request by independent researchers based on trial sponsors' data sharing policies. RESULTS: There were 316 industry-sponsored clinical trials with results presented in the FDA-authorized drug labels of the 30 sampled medicines. Of these trials, CSRs were available for public download from 70 (22%), with 37 available at EMA and 40 at Health Canada repositories. While pharmaceutical company platforms offered no direct downloads of CSRs, sponsors confirmed that CSRs from 183 (58%) of the 316 clinical trials were eligible for independent researcher request via the submission of a research proposal. Overall, 218 (69%) of the sampled clinical trials had CSRs available for public download and/or were eligible for request from the trial sponsor. CONCLUSION: CSRs were available from 69% of the clinical trials supporting regulatory approval of the 30 medicines sampled. However, only 22% of the CSRs were directly downloadable from regulatory agencies, the remaining required a formal application process to request access to the CSR from the study sponsor.
引用
- Hopkins AM, Modi ND, Rockhold FW, et al. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation. J Clin Epidemiol. 2024. PMID: 38219810. doi:10.1016/j.jclinepi.2024.111263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。